28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Aug
VELO
Som overskriften så pænt fortæller, så vil jeg gerne have Match tilbage. Og fordi at jeg tør og skri..
29
20 Aug
BIOPOR
  Bioporto kom med Q2 regnskab fredag den 8/8, og holdt efterfølgende en investor præsentation. Jeg ..
27
19 Aug
VELO
Jeg har rejst en del denne sommer, me har ind imellem lige været inde for at se, om der er nyt. Sene..
23
17 Aug
 
Janemlig, jeg synes det er forstemmende man kan leve med fri adgang til alle informationer og så all..
17
14 Aug
 
Normal 0 21 false false false NO-BOK X-NONE X-NONE ..
17
18 Aug
 
  Financial Times har i dag bragt en ganske interessant artikel. Federal Reserve har d. 5. August i ..
15
20 Aug
VWS
Tadaaa! Tillykke d'herrer. Det er en stor dag i Euroinvestors Vestas forum. Det her må være først..
13
16 Aug
 
Jeg sagde at jeg var blevet fartblind på aktiemarkedet i sidste uge. Jeg fik meget ud af de svar som..
13
20 Aug
VWS
Gud bedre det!   Vestas har en brutto margin på over 19 % og har lavet en opjustering som endda ser ..
12
17 Aug
FING-B
Nu læste jeg det igennem af generel interesse i biometri. Det svenske indlæg handler om udfordringer..
12

Tech Companies Send Criticism Along With NSA-Related Data -- Update

04/02/2014 00:06:00
By Danny Yadron Technology companies including Google Inc. and Microsoft Corp. released new figures on the amount of data requests they received from U.S. ..

U.S. Hot Stocks: Hot Stocks to Watch

03/02/2014 14:07:00
Among the companies with shares expected to actively trade in Monday's session is Herbalife Ltd. (HLF). Herbalife Ltd. (HLF) raised its fourth-quarter outl..

Pfizer Study Meets Primary Endpoints

03/02/2014 13:05:00
Pfizer Inc. (PFE) said Monday that a Phase 2 trial of its advanced breast cancer treatment met its primary endpoint. Pfizer said a study comparing the effec..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Heineken N.V. reports 2014 half year results
2
Novartis provides drug candidate compounds to TB Alliance
3
Artprice: the art market disruptor; IPO of its subsidiary artmarket.com
4
I. M. Skaugen SE : 1H Result 2014
5
Alcatel-Lucent announces early repayment of USD 1,750 million senior secured credit facility and release of attached pledges
Euroinvestor around the globe: Euroinvestor.dk | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 August 2014 01:21:28
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20140819.1 - EUROWEB6 - 2014-08-21 02:21:28 - 2014-08-21 01:21:28 - 1000 - Website: OKAY